Respiratory medicine · 2026
The impact of positive airway pressure (PAP) on severe Coronavirus Disease (COVID-19) among the patients with obstructive sleep apnea (OSA).
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Namiranian Khodadad, Tucker Lue-Yen, Folck Bruce F
Аннотация
BACKGROUND: Obstructive sleep apnea (OSA) has been proposed as a risk factor for severe Coronavirus Disease (COVID-19). We hypothesized that treating OSA with positive airway pressure (PAP) decreases the risk of severe COVID-19. To answer this question, the risk of severe COVID-19 was compared between PAP adherent and PAP non-adherent OSA patients.
METHODS: This is a retrospective cohort study of patients aged 18-89 with OSA and available data on PAP use who tested positive for SARV-COV-2 before 12/14/2020. The patients were divided into PAP adherent and PAP non-adherent groups based on their PAP use as recorded by the machine. Outcome is "severe COVID-19" (death, ICU admission, intubation, and/or acute respiratory failure) within 3 months of a first positive SARS-COV-2 test. Unadjusted and adjusted logistic regression analyses were performed to assess the association of PAP adherence with the outcome.
RESULTS: Of 256,163 patients with PAP adherence data (37.5% adherent), we found 13,533 with a positive SARS-COV-2 test (32.5% adherent), of which 1666 patients met the inclusion criteria. One-third of these patients were PAP adherent (n = 556, 33.4%). Severe COVID-19 occurred in 13 (2.3%) of adherent and 23 (2.1%) of non-adherent patients. Further analysis did not show any significant association of PAP adherence with severe COVID-19 when unadjusted (OR 1.21, 95%CI 0.88-1.66, p = 0.25) or when adjusting for demographics, selected comorbidities, and OSA severity (OR 0.88, 95%CI 0.43-1.81; p = 0.74).
CONCLUSION: In this retrospective analysis, the risk of severe COVID-19 was not different between PAP adherent and non-adherent OSA patients.
METHODS: This is a retrospective cohort study of patients aged 18-89 with OSA and available data on PAP use who tested positive for SARV-COV-2 before 12/14/2020. The patients were divided into PAP adherent and PAP non-adherent groups based on their PAP use as recorded by the machine. Outcome is "severe COVID-19" (death, ICU admission, intubation, and/or acute respiratory failure) within 3 months of a first positive SARS-COV-2 test. Unadjusted and adjusted logistic regression analyses were performed to assess the association of PAP adherence with the outcome.
RESULTS: Of 256,163 patients with PAP adherence data (37.5% adherent), we found 13,533 with a positive SARS-COV-2 test (32.5% adherent), of which 1666 patients met the inclusion criteria. One-third of these patients were PAP adherent (n = 556, 33.4%). Severe COVID-19 occurred in 13 (2.3%) of adherent and 23 (2.1%) of non-adherent patients. Further analysis did not show any significant association of PAP adherence with severe COVID-19 when unadjusted (OR 1.21, 95%CI 0.88-1.66, p = 0.25) or when adjusting for demographics, selected comorbidities, and OSA severity (OR 0.88, 95%CI 0.43-1.81; p = 0.74).
CONCLUSION: In this retrospective analysis, the risk of severe COVID-19 was not different between PAP adherent and non-adherent OSA patients.